Skip to content
stoqly

Corcept Therapeutics

CORT Nasdaq Pharmaceuticals Financials FY2016–FY2025

Corcept Therapeutics' revenue rose 12.8% to $761 million in fiscal 2025. Its operating margin was 5.9%, down from 20.3% a year earlier. Free cash flow was $142 million, down 27.7%. It paid out $173 million in dividends and buybacks, 122% of free cash flow. The diluted share count rose 5.7%.

Last close · Oct 23, 2026

$85.86

20.1%
Value it Compare
Revenue Total sales reported in the income statement.
$761M
12.8% vs prior year
Operating margin Operating income as a share of revenue.
5.9%
14.4 pts
Net income Profit after all expenses, interest and tax.
$99.7M
29.4%
Free cash flow Cash from operations minus capital spending.
$142M
27.7%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
15.7%
39.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$10.2B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $0.42 EPS (TTM)

What Corcept Therapeutics does

No business description yet.

Legal name
CORCEPT THERAPEUTICS INC
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001628280-26-011091
0001088856

Revenue and margins

Corcept Therapeutics had $761M of revenue in fiscal 2025, up 12.8% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 31.4% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $142M in fiscal 2025, 18.6% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Corcept Therapeutics returned $173M to shareholders in fiscal 2025, 122% of free cash flow. The diluted share count rose 5.7%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Corcept Therapeutics yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of $372M and divides by 120.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today — · peers 15.3x · sector 28.1x.

Balance sheet

Cash, debt and the ratios that show how comfortably Corcept Therapeutics can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $224M$432M$368M$383M$372M
Debt incl. finance leases $0.0M$0.0M$0.0M$0.0M$0.0M
Net debt / EBITDA −1.8x−3.8x−3.4x−2.8x−8.1x
Debt / equity 0.0x0.0x0.0x0.0x0.0x
Current ratio 5.6x6.9x4.4x3.4x2.9x
Quick ratio 5.5x6.8x4.3x3.3x2.9x
Total assets $424M$583M$622M$841M$837M
Total liabilities $47.9M$81.6M$115M$161M$189M
Shareholders' equity $376M$502M$507M$680M$648M
Net debt (− = net cash) −$224M−$432M−$368M−$383M−$372M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$34.8M

7 insiders

Of sales under plans

87%

$30.4M

DateInsiderTradeSharesPriceValueFiling
Oct 15, 2026 James N WilsonDirector Sold plan 10,000 $114.81 $1.1M Form 4
Sep 16, 2026 Roberto Wandenkolk VieiraPresident, Oncology Sold plan 296 $100.82 $0.0M Form 4
Sep 15, 2026 James N WilsonDirector Sold plan 10,000 $110.69 $1.1M Form 4
Sep 14, 2026 Joseph Douglas LyonSee Remarks Sold plan 10,000 $113.50 $1.1M Form 4
Sep 2, 2026 Roberto Wandenkolk VieiraPresident, Oncology Sold plan 58,333 $110.76 $6.5M Form 4
Sep 1, 2026 Sean MaduckSee Remarks Sold plan 25,000 $114.43 $2.9M Form 4
Aug 26, 2026 Kimberly ParkDirector Sold 26,685 $122.55 $3.3M Form 4
Aug 25, 2026 Sean MaduckSee Remarks Sold plan 30,955 $125.58 $3.9M Form 4
Aug 18, 2026 David L MahoneyDirector Sold plan 103,606 $118.25 $12.3M Form 4
Aug 17, 2026 Gary Charles RobbChief Business Officer Sold 10,000 $116.26 $1.2M Form 4
Aug 14, 2026 James N WilsonDirector Sold plan 10,000 $111.42 $1.1M Form 4
Aug 14, 2026 Sean MaduckSee Remarks Sold plan 3,664 $114.49 $0.4M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✕ ✕
Current ratio rose ✕ ✕ ✕
Share count didn't rise ✓ ✕ ✕
Gross margin rose ✕ ✕ ✕
Revenue rose relative to assets ✕ ✓ ✕
F-score 4 / 95 / 93 / 9
Accruals ratio −3.4%−7.8%−5.1%
Altman Z'' 11.6410.228.97

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Corcept Therapeutics CORT $10.2B 12.8% 5.9% 18.6% 15.7% — 3
Collegium Pharmaceutical COLL $746M 23.6% 23.0% 42.0% 53.4% 18.5x 6 Compare →
Amphstar Pharmaceuticals AMPH $1.1B −1.7% 19.5% 16.8% 9.9% 14.9x 6 Compare →
ANI Pharmaceuticals ANIP $1.6B 43.8% 12.6% 19.4% 15.9% 15.7x 6 Compare →
Acadia Pharmaceuticals ACAD $3.4B 11.9% 9.8% 9.8% — 8.9x — Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $81.3M $159M $251M $307M $354M $366M $402M $482M $675M $761M
Gross profit $79.3M $156M $246M $301M $348M $361M $397M $476M $664M $748M
Research and development $23.8M $40.4M $75.2M $89.0M $115M $114M $131M $184M $247M $255M
Operating income $10.2M $52.9M $89.5M $112M $128M $125M $113M $107M $137M $44.8M
Interest expense $2.0M — — — — — — — — —
Pretax income $8.1M $52.8M $92.2M $117M $132M $125M $116M $125M $162M $66.5M
Income tax $0.0M −$76.3M $16.7M $22.5M $25.6M $12.5M $14.8M $18.4M $20.3M −$33.2M
Net income $8.1M $129M $75.4M $94.2M $106M $113M $101M $106M $141M $99.7M
Diluted EPS $0.07 $1.04 $0.60 $0.77 $0.85 $0.89 $0.87 $0.94 $1.23 $0.82
Diluted shares 0.12B 0.12B 0.13B 0.12B 0.12B 0.13B 0.12B 0.11B 0.11B 0.12B
Cash flow
Cash from operations $18.4M $60.9M $116M $136M $152M $168M $120M $127M $198M $142M
Capital expenditure $0.2M $0.4M $0.3M $1.1M $1.2M $0.5M $0.4M $0.1M $2.2M $0.2M
Free cash flow $18.2M $60.5M $115M $135M $151M $167M $120M $127M $196M $142M
Depreciation and amortization $0.1M $0.1M $0.2M $0.7M $0.5M $1.1M $1.3M $1.0M $0.8M $1.1M
Stock-based compensation $7.1M $13.4M $23.7M $29.3M $33.5M $42.9M $42.4M $48.9M $61.4M $84.5M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $23.7M $31.0M $9.9M $0.0M $0.0M $0.0M $15.7M $173M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $23.7M $31.0M $10.0M $0.0M $0.0M $0.0M $15.7M $173M
Balance sheet
Cash and short-term investments $51.5M $88.7M $207M $276M $441M $224M $432M $368M $383M $372M
Total debt $14.7M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $65.7M $124M $237M $307M $479M $267M $499M $459M $472M $486M
Current liabilities $27.4M $29.6M $35.6M $38.8M $47.5M $47.5M $72.5M $105M $141M $166M
Inventory $2.3M $4.6M $4.7M $5.4M $4.9M $5.0M $6.1M $7.7M $12.4M $12.9M
Property and equipment, net $0.2M $0.5M $0.7M $1.1M $1.7M $1.0M $0.6M $0.2M $2.7M $1.9M
Total assets $68.8M $221M $312M $412M $572M $424M $583M $622M $841M $837M
Total liabilities $27.4M $29.6M $35.8M $41.1M $48.4M $47.9M $81.6M $115M $161M $189M
Shareholders' equity $41.4M $191M $276M $371M $523M $376M $502M $507M $680M $648M
Margins
Gross margin 97.5% 97.8% 97.9% 98.2% 98.4% 98.6% 98.7% 98.7% 98.4% 98.3%
Operating margin 12.5% 33.2% 35.6% 36.4% 36.2% 34.0% 28.0% 22.2% 20.3% 5.9%
EBITDA margin 12.6% 33.3% 35.7% 36.6% 36.4% 34.3% 28.3% 22.5% 20.4% 6.0%
Net margin 10.0% 81.1% 30.0% 30.7% 30.0% 30.7% 25.2% 22.0% 20.9% 13.1%
FCF margin 22.4% 38.0% 45.9% 44.1% 42.6% 45.8% 29.8% 26.2% 29.1% 18.6%
Returns
Return on capital — 99.0% 85.5% 109.6% 116.1% 95.4% 88.4% 87.6% 55.1% 15.7%
Return on capital employed 28.1% 45.5% 38.3% 34.4% 28.6% 27.7% 25.4% 20.9% 22.5% 6.5%
Return on equity 27.2% 111.2% 32.3% 29.1% 23.7% 25.0% 23.1% 21.1% 23.8% 15.0%
Return on assets 13.5% 89.3% 28.3% 26.0% 21.6% 22.6% 20.1% 17.6% 19.3% 11.9%
Growth
Revenue growth 61.7% 95.8% 57.8% 22.0% 15.5% 3.4% 9.8% 20.0% 39.9% 12.8%
Net income growth — 1,486.3% −41.6% 24.9% 12.6% 6.1% −9.9% 4.7% 33.0% −29.4%
EPS growth — 1,385.7% −42.3% 28.3% 10.4% 4.7% −2.3% 8.1% 30.9% −33.3%
FCF growth 484.6% 232.6% 90.6% 17.0% 11.6% 11.1% −28.4% 5.5% 55.0% −27.7%
Share count change 8.7% 7.2% 1.8% −3.3% 1.3% 1.4% −7.9% −3.6% 1.6% 5.7%
Financial health
Net debt / EBITDA −3.6x −1.7x −2.3x −2.5x −3.4x −1.8x −3.8x −3.4x −2.8x −8.1x
Debt / equity 0.4x 0.0x 0.0x 0.0x 0.0x 0.0x 0.0x 0.0x 0.0x 0.0x
Interest coverage 5.0x — — — — — — — — —
Current ratio 2.4x 4.2x 6.7x 7.9x 10.1x 5.6x 6.9x 4.4x 3.4x 2.9x
Quick ratio 2.3x 4.1x 6.5x 7.8x 10.0x 5.5x 6.8x 4.3x 3.3x 2.9x
Capital allocation
Capex / revenue 0.2% 0.3% 0.1% 0.4% 0.4% 0.1% 0.1% 0.0% 0.3% 0.0%
Stock comp / revenue 8.7% 8.4% 9.5% 9.6% 9.5% 11.7% 10.6% 10.2% 9.1% 11.1%
Payouts / FCF 0.0% 0.0% 20.5% 22.9% 6.6% 0.0% 0.0% 0.0% 8.0% 122.0%
Quality scores
Piotroski F-score 8.0 7.0 5.0 6.0 5.0 4.0 8.0 4.0 5.0 3.0
Altman Z'' −9.0 8.4 13.0 15.4 18.3 15.1 14.2 11.6 10.2 9.0
Accruals ratio −17.0% 47.1% −15.1% −11.6% −9.3% −11.1% −3.8% −3.4% −7.8% −5.1%

Source: SEC EDGAR XBRL filings (CIK 0001088856). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open